CAMPBELL, CA — (BusinessWire – June 8, 2017) – Saama Technologies, Inc., a leading big data and advanced analytics solutions company, today announced that industry luminary Rebecca Daniels Kush, Ph.D., has joined its Board of Advisors.
Dr. Kush founded Clinical Data Interchange Standards Consortium, Inc. (CDISC) in 1997 and served as its President and Chief Executive Officer until April 2017. CDISC now offers a suite of data standards that streamlines global clinical research in therapeutic areas that affect over 1.5 billion lives. These standards are now required for submissions for new drug applications to FDA and Japan’s PMDA. Dr. Kush has over 35 years of experience in clinical research, including positions with academia, the U.S. National Institutes of Health, a global CRO and biopharmaceutical companies in the U.S. and Japan. She is currently President of Catalysis, Inc. a consulting company focused on enterprising solutions to transform clinical research and accelerate a learning health system. She serves as the Scientific Innovation Officer for Elligo Health Research. She is also working with the International Academic Research Organization through the Translational Research Informatics Center in Japan. Dr. Kush earned a Ph.D. in Physiology and Pharmacology from the University of California (UCSD) School of Medicine in La Jolla, CA and has a B.S. in Chemistry and Biology from the University of New Mexico.
“I am delighted to join the Board of Advisors at Saama Technologies,” Said Dr. Kush. “Saama is leveraging their 20+ years of experience in big data analytics and the very standards we developed at CDISC to drive innovative solutions in the area of Patient Data Repositories (PDR) and Operational Data Repositories (ODR) – essentially delivering Clinical Data Management as a Service (CDaaS). I am excited about the Saama approach and believe that their solutions will have both a profound and beneficial impact to transform the way clinical research is done around the world today.”
Founder and CEO of Saama Technologies, Suresh Katta said, “Saama welcomes Dr. Kush to its advisory board. We are honored to have someone of Dr. Kush’s stature collaborating with us to deepen our understanding of how to best leverage data standards in processing large volumes of disparate clinical and operational data to support the life science industry.”
With the addition of Dr. Kush to its Board of Advisors, Saama is reinforcing its commitment to providing the Life Sciences Industry solutions that deliver impactful and actionable business outcomes.
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences, and the Global 2000. We are singularly focused on driving fast, flexible, impactful business outcomes for our clients through data and analytics. Our unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management and big data technologies. We blend manual and disconnected initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation.
Access Out-of-the-Box Features in 4 Weeks—Guaranteed.
Saama can put you on the fast track to clinical trial process innovation.